The topoisomerase IIα expression correlates with survival in patients with advanced Hodgkin's lymphoma

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1406-1411

  Provencio, Mariano ^a   Corbacho, Cesar ^a   Salas, Clara ^a   Millan, Isabel ^a   Espana, Pilar ^a   Bonilla, Felix ^a   Cajal, Santiago Ramon ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DOXORUBICIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PARAFFIN; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; SCHOOL CHILD; SEX DIFFERENCE; STAINING; TREATMENT OUTCOME;

EID: 0037390020     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hasenclever, D., and Diehl, V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. N. Engl. J. Med., 339: 1506-1514, 1998.
2. Sarris, A., Kliche, K., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F. B., McLaughlin, P., Rodriguez, M. A., Romaguera, J., Fritsche, H., Witzig, T., Duvic, M., Andreeff, M., and Cabanillas, F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol., 10: 433-440, 1999.
3. Binaschi, M., Capranico, G., De Isabella, P., Mariani, M., Supino, R., Tinelli, S., and Zunino, F. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int. J. Cancer, 45: 347-352, 1990.
4. Giaccone, G., Gazdar, A. F., Beck, H., Zunino, F., and Capranico, G. Multidrug sensitivity phenotype of human cancer cells associated with topoisomerase II expression. Cancer Res., 52: 1666-1674, 1992.
5. Van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willense, P. H., Zijstra, J. G., and de Vries, E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res., 51: 5915-5920, 1991.
6. Holden, J. A., Perkins, S. L., Snow, G. W., and Kjeldsberg, C. R. Immunohistochemical staining for DNA topoisomerase II in nonHodgkin's Lymphomas. Am. J. Clin. Pathol., 104: 54-59, 1995.
7. Yabuki, N., Sasano, H., Kato, K., Ohara, S., Toyota, T., Nagura, H., Miyaike, M., Nozaki, N., and Kikuchi, A. Immunohistochemical study of DNA topoisomerase in human gastric disorders. Am. J. Pathol., 149: 997-1007, 1996.
8. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki67. J. Immunol., 133: 1710-1715, 1984.
9. Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel, R. M., Banks, P. M., Foucar, K., Kjeldsberg, C. R., Levy, N., and Nathwani, B. N. Prognostic significance of the Ki67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group Trial. Blood, 83: 1460-1465, 1994.
10. Morente, M. M., Piris, M. A., Abraira, V., Acevedo, A., Aguilera, B., Bellas, C., Fraga, M., García del Moral, R., Gómez-Marcos, F., Menarquez, J., Oliva, H., Sánchez, Beato, M., and Montalban, C. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein I expression. Blood, 6: 2429-2436, 1997.
11. Brown, M. S., Holden, J. A., Rahn, M. P., and Perkins, S. L. Immunohistochemical staining for DNA topoisomerase Ha in Hodgkin's disease. Am. J. Clin. Pathol., 109: 39-44, 1998.
12. Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. N., and Tubiana, M. Report of the committee on Hodgkin's disease staging classification. Cancer Res., 31: 1860-1861, 1971.
13. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., and Tubiana, M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol., 7: 1630-1636, 1989.
14. De Vita, V. T., and Serpick, A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc. Am. Assoc. Cancer Res., 8: 13a, 1967.
15. Bonadonna, G., Zucali, R., Monfardini, S., De Lena, M., and Uslenghi, C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer (Phila.), 36: 252-259, 1975.
16. Bonadonna, G., Valagussa, P., and Santoro, A. Alternating noncross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Int. Med., 104: 739-746, 1986.
17. Urba, W. J., and Longo, D. Hodgkin's disease. N. Engl. J. Med., 10: 678-687, 1992.
18. Kaplan, E. L., and Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
19. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observations of each patients: II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
20. Cox, D. R. Regression models and lifetables. J. R. Stat. Soc., 34: 187-202, 1972.
21. Viviani, S., Bonadonna, G., Santoro, A., Bonafante, V., Zanini, M., Devizzi, L., Soncini, F., and Valagussa, P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J. Clin. Oncol., 14: 1421-1430, 1996.
22. Roy, P., Vaughan Hudson, G., Vaughan Hudson, B., Esteve, J., and Swerdlow, A. J. Long-term survival in Hodgkin's disease patients: a comparison of relative survival in patients in trial and those recorded in population-based cancer registries. Eur. J. Cancer, 36: 384-389, 2000.
23. Hermine, O., Haioun, C., Lepage, E., d'Agay, M. F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J. P., Diebold, J., Reyas, F., and Gaulard, P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des lymphomas de l'Adulte (GELA). Blood, 87: 265-268, 1996.
24. Piris, M. A., Pezzella, F., Martinez-Montero, J. C., Orradre, J. L., Villuendas, R., Sánchez-Beato, M., Cuena, R., Cruz, M. A., Martinez, B., and Pezella, F. P53 and bcl2 expression in high-grade B-cell lymphomas. Correlation with survival time. Br. J. Cancer, 69: 337-341, 1994.
25. Grogan, T. M., Lippman, S. M., Spier, C. M., Slymen, D. J., and Grogan, T. M. Independent prognostic significance of a nuclear proliferation antigen in a diffuse large cell lymphomas as determined by the monoclonal antibody Ki67. Blood, 71: 1157-1163, 1988.
26. Doussis, I., Pezzella, F., Lane, D. P., Gaffer, K. C., and Mason, D. Y. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am. J. Clin. Pathol., 99: 663-667, 1993.
27. Xerri, L., Bouabdallah, R., Camerlo, J., and Hassoun, J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum. Pathol., 25: 449-454, 1994.
28. Smolewski, P., Robak, T., Krykowski, E., Blasinska-Morawiec, M., Niewiadomska, H., Pluzanska, A., Chmielowska, E., and Zambrano, O. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin. Cancer Res., 6: 1150-1160, 2000.
29. Korkopoulou, P., Angelopoulou, M., Siakantari, M., Mitropoulos, F., Vassilakopoulos, T., Zorzos, H., Rassidakis, G., Androulaki, A., Ptsouris, E., Kittas, C., Davaris, P., and Pangalis, G. A. Evaluation of DMA topoisomerase IIα expression provides independent prognostic information in non-Hodgkin's lymphomas. Histopathology, 38: 45-53, 2001.
30. Taniguchi, K., Wakabayashi, T., Yoshida, T., Mizuno, M., Yoshikawa, K., Kikuchi, A., Nakashima, N., and Yoshida, J. Immunohistochemical staining of DNA topoisomerase IIα in human gliomas. J. Neurosurg., 91: 477-482, 1999.
31. Coleman, L. W., Perkins, S. L., Bronstein, I. B., and Holden, J. A. Expression of DNA topoisomerase I and DNA Topoisomerase II-α in testicular seminomas. Hum. Pathol., 31: 728-733, 2000.
32. Guinee, D. G., Holden, J. A., Benfield, J. R., Woodward, M. L., Przygodki, R. M., Fishback, N. F., Koss, M. N., and Travis, W. D. Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer (Phila.), 78: 729-735, 1996.
33. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., and Peterson, B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med., 327: 1478-1484, 1992.
34. Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M., Lathan, B., Paulus, U., Sieber, M., Ruffer, J. U., Sextro, M., Engert, A., Wolf, J., Hermann, R., Holmer, L., Stappert-Jahn, U., WinnerleinTrump, E., Wulf, G., Krause, S., Glunz, A., von Kalle, K., Bischoff, H., Haedicke, C., Duhmke, E., Georgii, A., and Loeffler, M. BEACOPP: a new regimen for advanced Hodgkin's disease. Ann. Oncol., 9 (Suppl. 5): S67-S71, 1998.
35. Korkolopoulou, P., Angelopoulou, M. K., Kontopidou, F., Tsenga, A., Patsouris, E., Thomas-Tsagli, E., Kittas, C., and Pangalis, G. A. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphoma: a multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology, 33: 240-247, 1998.